SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001819790-24-000043
Filing Date
2024-03-19
Accepted
2024-03-19 19:03:19
Documents
3
Period of Report
2024-03-15

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1710889381.html 4  
1 FORM 4 wk-form4_1710889381.xml 4 9936
2 EX-24 a2023-05x17secpoaseshane.htm EX-24 4198
3 a2023-05x17secpoaseshane001.jpg GRAPHIC 160494
  Complete submission text file 0001819790-24-000043.txt   236711
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Issuer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618
Business Address
Neervannan Seshadri (Reporting) CIK: 0001827584 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39614 | Film No.: 24765680